Brown Brothers Harriman & Co’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $438K | Buy |
1,932
+437
| +29% | +$77.8K | ﹤0.01% | 726 |
|
|
2026
Q1 | $258K | Buy |
1,495
+842
| +129% | +$156K | ﹤0.01% | 766 |
|
|
2025
Q4 | $130K | Buy |
653
+171
| +35% | +$31K | ﹤0.01% | 847 |
|
|
2025
Q3 | $75.4K | Buy |
482
+186
| +63% | +$29.5K | ﹤0.01% | 930 |
|
|
2025
Q2 | $44.9K | Sell |
296
-107
| -27% | -$14.3K | ﹤0.01% | 954 |
|
|
2025
Q1 | $60.7K | Buy |
403
+14
| +4% | +$2.35K | ﹤0.01% | 794 |
|
|
2024
Q4 | $71.8K | Buy |
389
+255
| +190% | +$49.1K | ﹤0.01% | 802 |
|
|
2024
Q3 | $26.4K | Buy |
134
+9
| +7% | +$1.87K | ﹤0.01% | 897 |
|
|
2024
Q2 | $25.8K | Sell |
125
-95
| -43% | -$21.5K | ﹤0.01% | 857 |
|
|
2024
Q1 | $59.6K | Hold |
220
| – | – | ﹤0.01% | 736 |
|
|
2023
Q4 | $52K | Buy |
220
+95
| +76% | +$18.7K | ﹤0.01% | 726 |
|
|
2023
Q3 | $24.5K | Sell |
125
-419
| -77% | -$86K | ﹤0.01% | 805 |
|
|
2023
Q2 | $114K | Sell |
544
-9,048
| -94% | -$1.8M | ﹤0.01% | 569 |
|
|
2023
Q1 | $1.94M | Buy |
9,592
+4,611
| +93% | +$1.04M | 0.02% | 177 |
|
|
2022
Q4 | $1.09M | Buy |
4,981
+1,008
| +25% | +$220K | 0.01% | 213 |
|
|
2022
Q3 | $782K | Buy |
3,973
+576
| +17% | +$124K | 0.01% | 244 |
|
|
2022
Q2 | $727K | Buy |
3,397
+293
| +9% | +$71.6K | 0.01% | 262 |
|
|
2022
Q1 | $881K | Buy |
3,104
+460
| +17% | +$142K | 0.01% | 266 |
|
|
2021
Q4 | $996K | Buy |
2,644
+67
| +3% | +$26K | 0.01% | 242 |
|
|
2021
Q3 | $1.06M | Buy |
2,577
+182
| +8% | +$75.6K | 0.01% | 217 |
|
|
2021
Q2 | $886K | Buy |
2,395
+2,304
| +2,532% | +$769K | 0.01% | 246 |
|
|
2021
Q1 | $26K | Sell |
91
-7
| -7% | -$1.95K | ﹤0.01% | 744 |
|
|
2020
Q4 | $24K | Sell |
98
-50
| -34% | -$11.9K | ﹤0.01% | 764 |
|
|
2020
Q3 | $34K | Buy |
148
+28
| +23% | +$5.81K | ﹤0.01% | 628 |
|
|
2020
Q2 | $21K | Hold |
120
| – | – | ﹤0.01% | 680 |
|
|
2020
Q1 | $15K | Buy |
120
+12
| +11% | +$1.8K | ﹤0.01% | 664 |
|
|
2019
Q4 | $16K | Sell |
108
-1,500
| -93% | -$208K | ﹤0.01% | 823 |
|
|
2019
Q3 | $213K | Hold |
1,608
| – | – | ﹤0.01% | 418 |
|
|
2019
Q2 | $228K | Hold |
1,608
| – | – | ﹤0.01% | 375 |
|
|
2019
Q1 | $234K | Buy |
1,608
+85
| +6% | +$11.2K | ﹤0.01% | 360 |
|
|
2018
Q4 | $172K | Buy |
1,523
+23
| +2% | +$2.88K | ﹤0.01% | 364 |
|
|
2018
Q3 | $202K | Buy |
+1,500
| New | +$185K | ﹤0.01% | 362 |
|
|
2018
Q1 | – | Sell |
-105
| Closed | -$11K | – | 872 |
|
|
2017
Q4 | $11K | Buy |
105
+90
| +600% | +$9.79K | ﹤0.01% | 740 |
|
|
2017
Q3 | $2K | Hold |
15
| – | – | ﹤0.01% | 712 |
|
|
2017
Q2 | $2K | Hold |
15
| – | – | ﹤0.01% | 726 |
|
|
2017
Q1 | $1K | Buy |
+15
| New | +$1.27K | ﹤0.01% | 773 |
|
Other funds holding CRL
AI
Brown Brothers Harriman & Co's CRL Position: Q2 2026 in Review
Brown Brothers Harriman & Co increased its Charles River Laboratories (CRL) stake by 29% in Q2 2026, buying an estimated $77.8K and bringing the position to 1,932 shares worth $438K. The position accounts for ﹤0.01% of the portfolio, ranked #726.
Brown Brothers Harriman & Co first reported a position in CRL in Q1 2017 and has held it in 36 quarters since. The position peaked at $1.94M in Q1 2023. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Brown Brothers Harriman & Co held 1,932 shares of Charles River Laboratories worth $438K as of Q2 2026.
- Brown Brothers Harriman & Co bought 437 Charles River Laboratories shares in Q2 2026, an estimated $77.8K.
- Charles River Laboratories made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #726 holding.
- Brown Brothers Harriman & Co first reported a position in Charles River Laboratories in Q1 2017 and has held it in 36 quarters since.
- Brown Brothers Harriman & Co's Charles River Laboratories position peaked at $1.94M in Q1 2023.
- 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.